| XLS |
|
€ million |
Jan.–Sep. |
Jan.–Sep. |
|
Profit after tax |
490.0 |
596.0 |
|
Depreciation/amortization/impairment losses/write ups |
1,253.5 |
776.5 |
|
Changes in inventories |
–87.5 |
–72.1 |
|
Changes in trade accounts receivable |
–74.7 |
–161.7 |
|
Changes in trade accounts payable |
–74.3 |
–24.6 |
|
Changes in provisions |
13.4 |
85.2 |
|
Changes in other assets and liabilities |
–120.6 |
113.6 |
|
Neutralization of gain/loss on disposals of assets |
–205.7 |
–3.2 |
|
Other non-cash income and expenses |
22.6 |
–6.7 |
|
Net cash flows from operating activities |
1,216.7 |
1,302.9 |
|
|
|
|
|
Purchase of intangible assets |
–35.8 |
–47.6 |
|
Purchase of property, plant and equipment |
–246.0 |
–254.2 |
|
Acquisitions |
–84.3 |
–4,845.7 |
|
Investments in financial assets |
–6.5 |
–11.1 |
|
Disposal of non-current assets |
557.3 |
21.7 |
|
Purchase/sale of marketable securities |
–21.3 |
2.1 |
|
Changes in financial assets covering pensions |
–5.0 |
–6.7 |
|
Changes in other financial assets |
–907.0 |
1,397.9 |
|
Net cash flows from investing activities |
–748.6 |
–3,743.4 |
|
|
|
|
|
Dividend payments |
–84.5 |
–73.1 |
|
Profit transfers to E. Merck KG and changes in reserves |
–233.0 |
–163.8 |
|
Changes in liabilities to E. Merck KG |
81.5 |
–9.8 |
|
Bonds issued |
– |
3,181.7 |
|
Changes in current and non-current financial liabilities |
–37.6 |
356.0 |
|
Net cash flows from financing activities |
–273.6 |
3,291.0 |
|
|
|
|
|
Changes in cash and cash equivalents |
194.5 |
850.5 |
|
Changes in cash and cash equivalents due to currency translation |
–2.2 |
–4.3 |
|
Cash and cash equivalents as of January 1 (Group balance sheet) |
943.7 |
541.4 |
|
Plus cash and cash equivalents previously in assets held for sale |
1.2 |
– |
|
Cash and cash equivalents as of September 30 |
1,137.2 |
1,387.6 |